UBS lowered the firm’s price target on Dentsply Sirona (XRAY) to $24 from $25 and keeps a Buy rating on the shares. While Dentsply Sirona reported “better” Q2 adjusted EBITDA, there was some noise below the line, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- DENTSPLY SIRONA: Hold Rating Amid Strong Earnings, Leadership Changes, and Market Challenges
- DENTSPLY SIRONA: Hold Rating Amidst Sales Pressure and Strategic Leadership Transition
- Dentsply Sirona Reports Q2 2025 Financial Results
- DENTSPLY SIRONA: Hold Rating Maintained Amidst Mixed Performance and Promising Margin Improvements
- Dentsply Sirona reports Q2 adjusted EPS 52c, consensus 50c